Three of them (GRB2, GNG2, CREB1) are the targets of approved non-oncological drugs (Pegademase bovine, Naloxone, Adenosine monophosphate, Citalopram, Halothane), thus illustrating MDS method potential in drug repurposing. This evidence concerns the gene GNG2 and myelodysplastic syndrome.